Emerging studies on retatrutide, a dual agonist for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, indicate encouraging outcomes in managing weight gain and type 2 diabetic condition. Early data from clinical experiments show notable reductions in body bulk and enhanced glucose levels. Additional research is directed on l